Drug Trial Radar · NCT07241039
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Nov 20, 2025
Primary completion
Apr 2029
Study completion Oct 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-711 as a monotherapy and in combination with budigalimab (ABBV-181) in adults with advanced squamous tumors. ABBV-711 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-711 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 220 adult participants will be enrolled in the study across 40 sites worldwide. In part 1, oral ABBV-711 tablets will be given in escalating doses alone to participants with squamous (sq) tumors. In part 2 oral ABBV-711 tablets will be given at a selected dose from part 1 to participants with squamous non-small cell lung cancer (sqNSCLC), or head and neck squamous cell carcinoma (HNSCC). In part 3, oral ABBV-711 tablets will be given in escalating doses in combination with intravenously (IV) infused budigalimab to participants with sq tumors. In part 4 oral ABBV-711 tablets will be given at a selected dose from part 3 in combination with IV infused budigalimab to participants with sqNSCLC, or HNSCC. The estimated duration of the study is up to approximately 5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent questionnaire, medical assessments, blood tests, and scans.
Conditions
- Advanced Squamous Tumors
Interventions
ABBV-711Drug
Oral Tablet
BudigalimabDrug
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 5 Years
- Best overall Response (BOR)Time frame: Up to Approximately 5 Years
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
City Of Hope Comprehensive Cancer Center /ID# 276550
Duarte, California · Recruiting
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432
Irvine, California · Recruiting
University of Chicago Medical Center /ID# 276638
Chicago, Illinois · Recruiting
START Midwest /ID# 272505
Grand Rapids, Michigan · Recruiting
Carolina BioOncology Institute /ID# 272380
Huntersville, North Carolina · Recruiting
Next Oncology Dallas /ID# 276659
Irving, Texas · Recruiting
Princess Margaret Cancer Centre /ID# 276852
Toronto, Ontario, Canada · Recruiting
CHUM - Centre hospitalier de l Universite de Montreal /ID# 277586
Montreal, Quebec, Canada · Recruiting
Rambam Health Care Campus- Haifa /ID# 276799
Haifa, Israel · Recruiting
Hadassah Medical Center-Hebrew University /ID# 276800
Jerusalem, Israel · Recruiting
The Chaim Sheba Medical Center /ID# 276798
Ramat Gan, Tel Aviv, Israel · Recruiting
National Cancer Center Hospital East /ID# 276585
Kashiwa-shi, Chiba, Japan · Recruiting
Kansai Medical University Hospital /ID# 276586
Hirakata-shi, Osaka, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.